QuidelOrtho (NASDAQ:QDEL) Issues FY 2026 Earnings Guidance

QuidelOrtho (NASDAQ:QDEL) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share guidance of 0.650-0.900 for the period, compared to the consensus EPS estimate of 1.850. The company issued revenue guidance of $2.5 billion-$2.6 billion, compared to the consensus revenue estimate of $2.7 billion.

QuidelOrtho Stock Performance

Shares of QDEL traded down $1.18 during mid-day trading on Thursday, reaching $16.32. 2,696,272 shares of the company’s stock were exchanged, compared to its average volume of 1,755,895. The business’s fifty day simple moving average is $15.70 and its 200-day simple moving average is $17.70. The stock has a market capitalization of $1.11 billion, a PE ratio of -0.92 and a beta of 0.68. QuidelOrtho has a 52-week low of $9.92 and a 52-week high of $35.58. The company has a debt-to-equity ratio of 1.33, a current ratio of 1.43 and a quick ratio of 0.80.

QuidelOrtho (NASDAQ:QDEL) last announced its earnings results on Thursday, August 6th. The company reported $0.13 earnings per share for the quarter, beating the consensus estimate of ($0.05) by $0.18. QuidelOrtho had a positive return on equity of 4.25% and a negative net margin of 45.57%.The company had revenue of $630.90 million for the quarter, compared to the consensus estimate of $618.72 million. QuidelOrtho has set its FY 2026 guidance at 0.650-0.900 EPS. On average, equities research analysts expect that QuidelOrtho will post 1.87 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms have recently commented on QDEL. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of QuidelOrtho in a research note on Friday, July 17th. Zacks Research upgraded shares of QuidelOrtho from a “strong sell” rating to a “hold” rating in a research report on Monday, June 15th. JPMorgan Chase & Co. boosted their price objective on QuidelOrtho from $11.00 to $12.00 and gave the stock an “underweight” rating in a report on Wednesday, July 1st. UBS Group reiterated a “neutral” rating and issued a $12.00 target price on shares of QuidelOrtho in a report on Thursday, May 7th. Finally, Wall Street Zen upgraded QuidelOrtho from a “sell” rating to a “hold” rating in a report on Sunday, June 28th. Four equities research analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, QuidelOrtho currently has an average rating of “Reduce” and an average price target of $13.62.

Hedge Funds Weigh In On QuidelOrtho

A number of large investors have recently bought and sold shares of QDEL. Invesco Ltd. lifted its position in shares of QuidelOrtho by 87.0% in the third quarter. Invesco Ltd. now owns 2,906,763 shares of the company’s stock valued at $85,604,000 after buying an additional 1,352,503 shares during the last quarter. Newtyn Management LLC increased its holdings in QuidelOrtho by 58.3% in the 3rd quarter. Newtyn Management LLC now owns 2,700,000 shares of the company’s stock worth $79,515,000 after purchasing an additional 994,332 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in shares of QuidelOrtho by 101.2% during the fourth quarter. Goldman Sachs Group Inc. now owns 1,755,401 shares of the company’s stock valued at $50,134,000 after purchasing an additional 883,077 shares in the last quarter. T. Rowe Price Investment Management Inc. grew its holdings in shares of QuidelOrtho by 7.4% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 11,832,098 shares of the company’s stock worth $337,925,000 after purchasing an additional 819,908 shares during the last quarter. Finally, State Street Corp raised its holdings in QuidelOrtho by 23.3% in the 2nd quarter. State Street Corp now owns 2,700,940 shares of the company’s stock valued at $77,841,000 after buying an additional 510,291 shares during the last quarter. Institutional investors and hedge funds own 99.00% of the company’s stock.

About QuidelOrtho

QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.

The company’s product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers.